After restricting the analysis to patients with a BRAF wild-type tumor, PIK3CA mutation was significantly associated with poorer overall survival (HR 1.51, 95% CI 1.04–2.19, P = 0.03) compared with wild-type PIK3CA (Figure 4B). The gene discussed is PIK3CA; the disease is neoplasm.